SLBio

SL BIO is a Taiwan-based biotech company focused on early-stage cell and gene therapy programs for oncology and regenerative medicine. The company is developing preclinical immune-cell platforms including Armed-T and allogeneic gamma delta T-cell programs for hard-to-treat cancers such as B cell leukemia, glioblastoma, and pancreatic cancer. In parallel, it is building cell-free and exosome-related formulation products, including milk-derived extracellular vesicle materials and cosmetic products. SL BIO presents itself as a platform-oriented company aiming to industrialize scalable cell therapy manufacturing and translational immune-oncology development. The company has pursued a public listing through a business combination with Horizon Space Acquisition II Corp. via SL Science Holding Limited.